医学
突变体
抗体-药物偶联物
曲妥珠单抗
表皮生长因子受体
结合
肺癌
内科学
癌症研究
肿瘤科
抗体
单克隆抗体
癌症
生物
乳腺癌
免疫学
基因
遗传学
数学
数学分析
作者
Bob T. Li,Egbert F. Smit,Yasushi Goto,Kazuhiko Nakagawa,Hibiki Udagawa,Julien Mazières,Misako Nagasaka,Lyudmila Bazhenova,Andreas Saltos,Enriqueta Felip,Jose M. Pacheco,M. Pérol,Luis Paz‐Ares,Kapil Saxena,R. Shiga,Yun Cheng,Suddhasatta Acharyya,Patrik Vitazka,Javad Shahidi,David Planchard,Pasi A. Jänne,DESTINY-Lung Trial Investigators
标识
DOI：10.1056/nejmoa2112431
摘要
Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody–drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively.
科研通智能强力驱动
Strongly Powered by AbleSci AI
shinysparrow
gjww
SOLOMON
star
cctv18
benben
寻道图强
爱鱼人士
Cactus
张泽崇
HGalong
凤凰
酸化土壤改良
宜醉宜游宜睡
坚强的广山
阿大呆呆
liv
Noel
互助遵法尚德
amateur
皖公网安备34019202002308
